Graves Ophthalmopathy Clinical Trial
Official title:
Exophthalmometry With 3D Face Scanners
This study investigates diagnostic methods to measure eyeball protrusion with a smartphone face scanner compared to the traditional Hertel exophthalmometer. The study aims to validate a new reliable, fast and convenient smartphone app to measure the protrusion of the eyeball in different diseases such as Graves' disease, orbital tumors, orbital fractures or orbital inflammation, as well as other rare diseases.
BACKGROUND: Accurate and reproducible measures of abnormal eyeball protrusion are important for diagnosing different causes of exophthalmos, as well as following patients with Grave's orbitopathy and retroorbital tumors. The current clinical gold standards for measuring abnormal eyeball protrusion is the Hertel exophthalmometer, which is prone to reading errors and inconvenient to use. OBJECTIVE: The purpose of the EX3D-project is to replace the historic Hertel Exophthalmometer with a state-of-the-art mobile smartphone app that every ophthalmologist can carry in his pocket. METHODS: The investigators developed an accurate and easy to use method for measuring abnormal eyeball protrusion using the TrueDepth camera of the iPhone 11 in comparison with a high-resolution 3D scanner as a reference to compare with the Hertel Exophthalmometer. OUTCOMES: 1. Accuracy and precision of 3D face-scanner and iPhone in comparison to Hertel Exophthalmometer. 2. Test re-test reliability in comparison to Hertel Exophthalmometer. 3. Inter-operator reliability against Hertel Exophthalmometer. 4. Patients before and after exophthalmos changing treatment. 5. Applicability in daily clinical practice. BROADER IMPACT: The invention makes exophthalmometry quick, easy and objective. A mobile smartphone application would replace measurements with the traditional Hertel Exophthalmometer, which are cumbersome, prone to reading errors and have a poor inter-rater reliability as well as test-retest reliability. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05532072 -
Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy.
|
Early Phase 1 | |
| Completed |
NCT01727973 -
Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06112340 -
A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05678374 -
Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease
|
||
| Recruiting |
NCT03708627 -
Bimatoprost as a Treatment for Graves' Orbitopathy
|
Early Phase 1 | |
| Withdrawn |
NCT01379196 -
Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06275373 -
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
|
||
| Recruiting |
NCT06226545 -
A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease
|
Phase 2 | |
| Recruiting |
NCT05126147 -
Hydroxychloroquine in Mild Graves' Orbitopathy
|
Phase 4 | |
| Recruiting |
NCT01999790 -
Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy
|
N/A | |
| Recruiting |
NCT03066076 -
Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy
|
Phase 3 | |
| Active, not recruiting |
NCT03122847 -
Glucocorticoids and Bone in Graves' Ophthalmopathy
|
||
| Terminated |
NCT01893450 -
Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment
|
N/A | |
| Completed |
NCT00348413 -
Thyroid Treatment Trial
|
N/A | |
| Completed |
NCT03498417 -
Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' Orbitopathy
|
||
| Not yet recruiting |
NCT04598815 -
Sirolimus for Graves' Orbitopathy (GO)
|
Phase 2 | |
| Terminated |
NCT01114503 -
A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease
|
Phase 2 | |
| Completed |
NCT05775185 -
Therapeutic Efficacy of Orbital Radiotherapy in Patients With Graves' Orbitopathy
|
||
| Completed |
NCT05793359 -
Comparison of the Effectiveness of Two Glucocorticoid Regimens for Treatment of Graves' Orbitopathy
|
||
| Recruiting |
NCT02203682 -
Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy
|
Phase 2 |